CollPlant Biotechnologies
CLGN
20 hedge funds and large institutions have $14.3M invested in CollPlant Biotechnologies in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
25% more funds holding
Funds holding: 16 → 20 (+4)
0.02% more ownership
Funds ownership: 1.56% → 1.58% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $19.5M → $14.3M (-$5.14M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$414K |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$213K |
| 3 |
SQA
Simon Quick Advisors
Morristown,
New Jersey
|
+$144K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$118K |
| 5 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$71.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
-$899K |
| 2 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$31.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$7.58K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3K |
| 5 |
Morgan Stanley
New York
|
-$1.84K |
CLGN Hedge Fund Activity: Q2 2022 in Review
20 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q2 2022, worth a combined $14.3M — down 26% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CLGN positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was LPL Financial, opening a new position worth an estimated $414K. The largest seller was Investment Management of Virginia, cutting an estimated $899K.
- 20 institutional investors held CollPlant Biotechnologies (CLGN) as of Q2 2022, up from 16 in Q1 2022.
- Funds reported $14.3M of CollPlant Biotechnologies stock for Q2 2022, down 26% quarter-over-quarter.
- 7 funds opened new CollPlant Biotechnologies positions in Q2 2022 and 3 closed out, a net change of +4 holders.
- The largest CollPlant Biotechnologies buyer in Q2 2022 was LPL Financial, an estimated $414K added.
- The largest CollPlant Biotechnologies seller in Q2 2022 was Investment Management of Virginia, an estimated $899K sold.
Based on aggregated 13F filings for Q2 2022.